Middletown Life

Author: Tempest Therapeutics

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

April 14, 2026
Tempest Reports Year End 2025 Financial Results and Provides Business Update

March 30, 2026
Tempest Therapeutics Announces Up To $6 Million Private Placement

March 23, 2026
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

March 11, 2026
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

February 25, 2026
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

February 13, 2026
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

February 12, 2026
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

January 20, 2026